Unveiling the Secrets of Health: The Human Genetics Market's Impact on Disease Prevention
The global human genetics market is expected to have a market value of USD 65.18 Billion by 2032.
The Human Genetics Market is witnessing a transformative era
driven by advancements in genomics and human molecular genetics. Genomics, the
study of an organism's complete set of DNA, is at the forefront of this
revolution, enabling researchers and healthcare professionals to delve into the
intricacies of human genetic information. As a result, the market is
experiencing unprecedented growth with a focus on personalized medicine,
genetic testing, and targeted therapies.
Human
molecular genetics, a subfield of genetics that explores the
molecular mechanisms underlying genetic traits and disorders, plays a pivotal
role in understanding the genetic basis of various diseases. The integration of
genomics and human molecular genetics has paved the way for breakthroughs in
diagnostics, treatment, and drug development.
The demand for genetic testing services has surged, driven by
the increasing awareness of personalized healthcare and the potential to
uncover individualized treatment options. The Human Genetics Market is
characterized by collaborations between biotechnology companies, research
institutions, and healthcare providers to leverage genomic data for precision
medicine.
Major Key Players:
MRFR recognizes Human
Genetics Companies are— Myriad Genetics (US), Synlab Group
(Germany), Eurofins Megalab S.A (Spain), Biomarker Technology (US), Echevarne
Laboratory (Spain), Elabscience Biotechnology Inc (US), NIMGenetics
(Spain), Sistemas Genómicos (Spain), FullGenomics
(Spain), GENinCode (UK), Atrys Health (Spain), Genyca
(Spain), Igenomix (India), Genologica (Spain), Bode Technology
Group Inc (US).
Segmentation
The global human genetics market is segmented into
application, end user and region. The application segment is further segmented
into wellness & E-commerce, preventive medicine, diagnostic &
treatment. The diagnostic & treatment segment is further sub-segmented into
oncology, cardiology, assisted reproduction, neurology, gynecology,
others.
The neurology segment is further sub-segmented into
neuropediatric, others. The test segment is further segmented into
NIPT, carrier testing, pharmacogenomic testing, karyotype
testing, thrombophilia testing, septin 9 biomarker
testing, NGS, others. The NGS segment is further sub-segmented into
oncology, cardiology, others.
Regional Analysis
The global human molecular genetics market, based on region,
has been divided into
US, Canada, UK, Germany, Spain, Japan, others.
The human genetics market in the US benefits from a high
healthcare expenditure, increasing demand for genetic testing by the
population, and high public awareness regarding early detection of diseases and
preventive care. Moreover, the availability of reimbursements in the US for
genetic tests further improves market growth in the country. For instance, in
October 2019, United HealthCare Services, Inc. (US), the largest health insurance
company in the US, started providing insurance coverage for multi-panel genetic
testing. According to the National Institutes of Health (NIH), in July 2023,
over 77,000 genetic tests are currently used in the US, and more are under
development.
Public-funded genetic testing in Canada is highly restricted
and is only available to a select few who fall into certain criteria, such as a
family history of cancer and early onset of cancer. Additionally, people in
Canada who want their genetic testing done can opt for direct-to-consumer
genetic tests such as color and invitae. Results from these tests can then be
consulted with genetic counselors. Furthermore, there are human genetics
programs to test patients with genetic disorders across Canada. For instance, the
Hereditary Cancer Program is based in British Columbia, Canada, conducting
genetic counseling and tests to detect hereditary cancer.
Clinically directed genetic testing has been available for
several decades in the NHS for predictive testing for family members and
molecular genetic investigation of a clinical presentation. Genomic health data
in the UK is generated in three major areas, including large-scale research
programs, the healthcare system, and purchasing of direct-to-consumer genetic
testing. Moreover, the rise in the number of initiatives undertaken by the
public as well as private organizations is further aiding the market growth.
For instance, in April 2023, GEN inCode UK Limited announced its collaboration
with Royal Brompton and Harefield hospitals (RB&H) for providing
cardiovascular disease clinical genetic testing and reporting. In August 2023,
DnaNudge announced the completion of its Series A investment round of USD 60
million led by Ventura Capital
The rising prevalence of genetic disorders, cancer, increasing
awareness and acceptance regarding personalized medicines, and growing focus on
R&D activities contribute to the country's growth. As per the data
published by Global Cancer Observatory in March 2023, cancer accounted for
628,516 new cases and 252,065 deaths in Germany in 2023. In addition, the
government is implementing a number of favorable and collaborative policies to
incorporate genetic testing into the healthcare system and provide insurance
reimbursements to citizens, which, in turn, is driving the market growth.
Browse Related Reports:
For More Information, Please Visit @ Market Research Future
Comments
Post a Comment